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Abstract
This article is the first of a series on pharmacological interactions involving medicaments commonly prescribed and/or used 
in odontology: vasoconstrictors in local anaesthetics and anti-inflammatory and anti-microbial analgesics.  The necessity 
for the odontologist to be aware of adverse reactions as a result of the pharmacological interactions is due to the increase 
in medicament consumption by the general population. There is a demographic change with greater life expectancy and 
patients have increased chronic health problems and therefore have increased medicament intake. The presence of adre-
naline (epinephrine) and other vasoconstrictors in local odontological anaesthetics is beneficial in relation to the duration 
and depth of anaesthesia and reduces bleeding and systemic toxicity of the local anaesthetic. However, it might produce 
pharmacological interactions between the injected vasoconstrictors and the local anaesthetic and adrenergic medicament 
administered exogenically which the odontologist should be aware of, especially because of the risk of consequent adverse 
reactions. Therefore the importance of conducting a detailed clinical history of the general state of health and include all 
medicaments, legal as well as illegal, taken by the patient.
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Characteristics of pharmacological interactions
* Concept of pharmacological interaction
A pharmacological interaction is the modification of the phar-
madynamics and/or the pharmakinetics of the medicament 
as a result of the treatment together with other medicaments, 
dietary factors (nourishment, diet, medicinal plants), social 
habits (smoking, alcohol consumption) or underlying pa-
thologies. In pharmacological interactions there will always 
be a medicament objective (MO), which will modify its 
effects and a medicament accelerator (MA) which modifies 
the effects of the latter. The characteristics of the potential 
MO are potential intense effects, undesirable serious dose 
dependency, narrow therapeutic index, stressed dose-response 
curve (small changes in the dose produce great changes in 
the plasma concentration) and that the basic illness closely 
depends on the medicament in question.
* Mechanisms of the pharmacological interactions
The pharmacological interactions can be produced through 
one or various mechanisms at the pharmakinetic and/or 
pharmadynamic levels (1).
1) Pharmakinetic. When a medicament alters the absorp-
tion, distribution, metabolism or renal excretion of another 
medicament.  
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-Absorption: Inhibition of the absorption of the medicament 
objective by physical or chemical means. This Pharmacolo-
gical Interaction (PI) is avoidable administering the medica-
ments at three or four hour intervals.
-Distribution: by competing for adhering to plasma pro-
teins.
-Metabolism: the enzymatic systems involved in the bio-
transformation of the majority of the medicaments are found 
principally in the smooth endoplasmic reticulum of the liver, 
which contains an important group of oxidative enzymes ca-
lled oxidases of mixed or mono-oxigenase function. Here the 
cytochrome family highlights the P450 cytochrome system 
(2). The following is the nomenclature of these enzymes: 
CYP followed by the number that represents the family of 
isoenzymes. This is followed by letter that represents the 
subfamily and then another number representing the indivi-
dual gene (e.g. CYP3A4). There are more than 30 isoenzymes 
of the P450 cytochrome of which the more important are 
CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4. The 
isoform CYP3A4 is the most abundant of the cytochrome 
family in the liver and human intestine. In pharmacological 
interactions at the metabolism and biotransformation level 
(the most important) an enzymatic induction or inhibition 
can be produced. 
During enzymatic induction the MA induces the metabolism 
of the MO, reducing its plasma concentration and therefore 
its efficiency. For induction to occur it is necessary that the 
medicaments share the same enzymes and that the MA is ca-
pable of inducing enzyme synthesis, a procedure which takes 
between one and two weeks. During enzymatic inhibition the 
MA inhibits the metabolism of the MO, increasing its plasma 
concentration and the risk of toxicity. In this case the effects 
are immediate (3). 
-Renal excretion of other medicaments:  the interactions at 
this level are less important.
 2) Pharmacodynamic. The combination of two medicaments 
which have a similar pharmacological action generally produ-
ce additive or synergic effects for both desired or undesired 
results. Medicaments with contrary pharmacological effects 
are antagonistic. The adverse effects as a result of this inte-
raction can be prevented by monitoring and adjusting the 
doses.
* Clinical repercussions of pharmacological interactions
The pharmacological interactions are responsible for 4.4% of 
hospitalizations attributed to medicaments and represent 4.6% 
of all adverse reactions by medicaments in hospitalized pa-
tients. The spectrum of medicament-medicament interactions 
is so wide that it can range from those that are not clinically 
important to those that represent a risk of severe adverse reac-
tion in the patient. It is essential to identify and select those in-
teractions according to clinical and therapeutic repercussions 
(Table 1) (4). In a young patient a pharmacological interaction 
can pass unnoticed, however, in an adult it can show up as a 
severe adverse reaction and can sometimes also be wrongly 
interpreted as a worsening of the illness, poor adherence of 
treatment or even inefficacy of some of the medicaments. 
The factors which make an interaction between medicaments 
clinically relevant are index or therapeutic margin, affinity 
of the enzyme for the medicament, dose, age, sex, pathology 
and of course ingestion of other medicaments.
* Medicaments of risk in pharmacological interactions
Medicaments which can probably produce pharmacological 
interactions have common characteristics. There are four 
pharmacological groups which should be taken into account 
when carrying out a clinical history suspected of producing 
possible interactions:
1) Medicaments which act in the gastrointestinal tract or 
which alter intestinal mobility.
2) Medicaments with a high affinity for plasma proteins 
which can displace other medicaments. In this group the 
odontologist should always be alert to include non-steroid 
anti-inflammatories (NSAI) which are prescribed daily in 
dental   practice.
3) Medicaments which modify liver metabolism. These 
are divided into two groups, inductors and inhibitors. The 
inductor medicaments stimulate the metabolism of other 
medicaments. The inhibitors inhibit metabolism.
4) Medicaments which alter renal function and clear up other 
medicaments (e.g. penicillin, cefalosporin) (3).
* Therapeutic index
The therapeutic index of a medicament is defined as the quo-
tient between the minimum efficiency concentration and the 
minimum toxicity concentration. If a medicament is affected 
by an interaction it will have more clinical repercussions if 
the medicament presents a narrow therapeutic margin. The 
odontologist should   be aware that the lower the therapeutic 
index of the medicament the higher the risk of producing 
a pharmacological interaction. Consequently this should 
be taken into account when making up a clinical history: it 
is important to be aware  that the following medicaments 
present a narrow therapeutic margin: hypoglucemics, oral 
anticoagulants, antiepileptics, antiarrhythmics, cardiotonic 
glucosides, oral anticonceptives, aminoglucosides, antineo-
plastics, medicaments of the central nervous system (CNS 
like lithium salts, antidepressors and neuroleptics (5). Once 
the general mechanisms of the pharmacological interactions 
have been clarified the pharmacological interactions of the 
vasoconstrictors (epinephrine) will be described in this first 
article which would be of interest for the odontologist because 
of the clinical repercussions which could be derived. Also the 
norm of action to prevent the appearance of adverse reac-
tions derived from these interactions making odontological 
practice more secure when administering local anaesthetics 
with vasoconstrictors.
Epinephrine and adrenergic system
The adrenergic vasoconstrictors are commonly used thera-
peutic agents in odontology. The most used vasoconstrictor is 
adrenaline, also called epinephrine (from Greek epi, up, and 
nefron, kidney) which is injected in combination with local 
E22
Med Oral Patol Oral Cir Bucal. 2009 Jan 1;14 (1):E20-7.                                                                                                                                                             Interactions of vasoconstrictors in odontology                                                                            Med Oral Patol Oral Cir Bucal.  2009 Jan 1;14 (1):E20-7.                                                                                                                                                          Interactions of vasoconstrictors in odontology
anaesthetics to eliminate pain (6). Epinephrine differs from 
noradrenalin, or norepinephrine, in that it has a more rapid 
and shorter effect. Epinephrine is a catecholamine monoami-
ne (belonging to the group of catecholamines which have a 
catechol group and a radical amine) sympathicomimetically 
derived from phenylalanine and tyrosine amino acids. In 
general, the catecholamines act on the sympathetic nervous 
system provoking different effects mainly through the action 
on adrenergic receptors. 
The adrenergic system is composed of alpha and beta, and 
various subtypes (beta1 and 2 and alpha 1 and 2). The beta 
1 receptors increase cardiac frequency and beta 2 receptors 
increase vasodilatation of the vascular bases at the pulmonary 
level. The action of the beta adrenergic system is principally 
systemic and those of the alpha adrenergic are peripheral with 
some systemic action. The stimulation of the alpha receptors 
increases vasoconstriction at the local peripheral circulation 
with a limited systemic activity. The stimulation of beta 1 
tends to raise arterial pressure while beta 2 tends to reduce 
it. The alpha stimulation system increases arterial pressure 
non dramatically (7). Epinephrine is the most potent alpha 
receptor. It is 2 to 10 times more active than noradrenaline 
and more than 100 times more potent than isoproterenol (8). 
Interest in the use of vasoconstrictor in odontology is due 
to the fact that the majority of local anaesthetics produce a 
dilatation of blood vessels (9). Therefore the addition of a 
vasoconstrictor, like epinephrine, reduces local blood flow 
(in oral mucous, submucous and periodontium it produces 
a selective alpha stimulation) resulting in vasoconstriction, 
delayed rate of absorption of local anaesthetic and prolongs 
its local effect, always taking into account that epinephrine 
should be used at a low concentration (10).
It is important to know the concentration of the vasoconstric-
tor which a phial of local anaesthetic contains. Generally the 
capacity of a phial of local anaesthetic is 1.8 ml. A concen-
tration of 1:100,000 epinephrine usually means 0.01 mg of 
epinephrine in 1 ml of anaesthetic solution, therefore a phial 
of local anaesthetic at this concentration of vasoconstrictor 
contains 0.018 mg of epinephrine (18 micrograms).
Interaction of vasoconstrictors with tricyclic anti-
depressors
Tricyclic antidepressors such as imipramine, amitriptyli-
ne and doxepin were the first medicaments used for the 
treatment of depression and other behavioural pathologies 
(11) (Table 2). They are the better known (and more effec-
tive) antidepressors and the standard by which to compare 
other antidepressor groups. The disadvantage is that it has 
many secondary effects, above all in elderly people. The 
most serious being disturbance of auricle-ventricle conduc-
Category of Pharmacological 
Interaction
Clinical Importance
Tipo A Without importance 
Tipo B Effect unestablished 
Tipo C
Possible therapeutic effect change or adverse effects. Avoided by 
adjusting doses.
Tipo D
Severe adverse effects. No therapeutic effects. Doses adjusted with 
difficulty. Avoid contact with e.g. Warfarine
TRICYCLICS HETEROCYCLICS SIRS* MAOI** Non selective MAOI
Amytriptiline 
Clomipramine
Dotiepine Doxipine
Imipramine
Nortriptiline 
Trimipramine
Maprotiline
Miaserine
Mirtazapine
Trazodone
Bupropion Citaloprane
Duloxetine Escytaloprane
Flouxetine
Fluvoxamine Paroxetine
Sertraline
Venlafaxine
Moclobemide
Phenylzine 
Nialamide
Tranylcipromine
Table 1. Classification of pharmacological interactions according to clinical relevance. 
Department of Pharmacology, Huddings Hospital, Stockholm, Sweden *
* FASS (Pharmaceutical Specialities in Sweden). Stockholm: INFO Lakemedelsinformation AB (Drug information), 
1997.URL: http://www.fass.se (Swedish).
Table 2. Classification of antidepressives in function of pharmalogical action.
* SIRS: selective inhibitors of recaptation of serotonin
**MAOI: monoaminooxidase inhibitor
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tion. Nowadays it is suggested for depressive disturbances 
in the elderly with melancholy when other antidepressors 
are inefficient. They are a pharmacological group which 
receive their name from their chemical structures which 
include a chain of three rings (Figure 1). The mechanism of 
tricyclic antidepressors is based on their capacity to inhibit 
the recaptation of neurotransmittors by neuronal receptors 
(adrenaline, noradrenaline) and serotonine, thus increasing 
its concentration. The result is the potentiation of the activity 
of these neurotransmittors.  This also blocks the muscarine 
receptors and the alpha 1 adrenergics which directly depresses 
the myocardium (Figure 2).
The principal mechanism by which noradrenaline is elimina-
ted from the adrenoreceptor is by inactivating it so that the 
concentration of the noradrenaline outside the neuron can 
increase. Consequently if more noradrenaline is diffused in 
the organism (or any other direct action alpha or beta agonist) 
a massive stimulation of the cardiovascular adrenergic recep-
tors is produced implicating an increase in arterial pressure 
due to an excess of sympaticometical amines in the synaptic 
spaces producing a respective response. This is the reason 
why the action of the tricyclic antidepressors can further 
modify the cardiovascular response to the vasoconstrictors 
used in odontology (12). There is discrepancy among authors 
regarding the pharmacological interaction of tricyclic-epine-
phrine antidepressors and the adverse reactions resulting from 
this interaction. Some deny the existence f this interaction 
arguing that epinephrine presents a vasodilatatory effect on 
acting on the beta 2 adrenergenic receptors counter arresting 
its vasoconstrictory action (6). Others suggest using low doses 
of epinephrine in local anaesthetics in odontological opera-
tions in out-patients can normally produce small changes in 
arterial pressure. As the cardiovascular state of the patients 
is not monitored the cardiac rhythmic changes can pass un-
noticed or wrongly diagnosed as an anxiety or hypersensitive 
response. Experimental studies are carried out over a short 
period of time during which the patient is receiving tricyclic 
antidepressors. Some authors and laboratories argue that the 
administration of tricyclic antidepressors during large periods 
of time can produce a desensitization of vasoconstrictors and 
a reduction of interaction risks (6).
However, there are experimental studies in both humans 
and animals which show a significant interaction between 
tricyclic antidepressors and adrenergic vasoconstrictors (13) 
and have identified various unpublished tricyclic antidepres-
sor-epinephrine interactions. The most important changes 
produced as a result of this interaction are a significant in-
Fig. 1. Tricyclic antidepressors chemical structure.
Fig. 2.  Mechanism of the action of tricyclic antidepressors.
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crease in systolic arterial pressure, disrhythmia and ectopic 
focus in cardiac conduction (14). Normally in odontology 
it is important to find out beforehand if the patient is being 
treated with tricyclic antidepressors and then to assume the 
existence of an active pharmacological interaction between 
tricyclic antidepressors and vasoconstrictors (15). Preventive 
measures include previous aspiration to discard intravenous 
injection and the use of phelypresine as a sure alternative to 
other sympatheticomimeticos in these patients.
Vasoconstrictors like levonordephrin or norepinephrine 
should never be used. Likewise gum cleaning filaments 
impregnated with epinephrine should not be used because 
of the possibility of rapid absorption across the gum gro-
oves and adjacent tissues (16). It is recommended not to use 
more than 1:100,000 concentration of epinephrine in local 
anaesthetics and the dose of local anaesthetic should be 1/3 
the normal dose for patients not taking tricyclic antidepres-
sors. Additional injections can be safely administered after 
30 minutes. The epinephrine dose should not be more than 
0.054 mg (three phials of 1:100,000) (3). It is an established 
interaction and potentially dangerous for life and capable of 
causing permanent damage (13). If this reaction is produced 
it can be controlled via an alpha adrenergic antagonist like 
phentolamine.
Interaction of vasoconstrictors with beta blockers
Beta blockers act by antagonizing the beta adrenergic re-
ceptors. They are commonly used for treating hypertension, 
angina, and cardiac arrhythmia. They act by competitively 
blocking the stimulation of beta receptors by endogen cate-
cholamines, epinephrine and norepinephrine. They also block 
the stimulation when exogenic adrenergic medicaments are 
administered. The specificity of its action on beta receptors 
could be non selective (blocking beta 1 cardiac receptors and 
beta 2 in blood vessels) and cardio selective beta 1 (preferen-
tially blocking beta 1 receptors at the cardiac level (1,3).
When epinephrine is absorbed at the systemic level it is not a 
pure vasoconstrictor as it acts on alpha 1 and beta 2 adrenergic 
receptors. However, if a beta blocker is active and produces 
a systemic absorption of epinephrine then the effects of the 
beta 2 vasodilators of epinephrine are blocked and can only 
act on alpha 1 receptors. Propranolol is the beta blocker 
the odontologist has to take into consideration when using 
epinephrine in local anaesthetics. Propranolol, blocks beta 2 
vasodilatator receptors which are found on the walls of the 
vessels of the skeletal muscles and other tissues suggesting 
that epinephrine acts at the vessel level as a pure stimulant 
of alpha adrenergic receptors (5,17).
Studies have shown an increase in systolic and diastolic arte-
rial pressure of 15-33 mmHg and 14-21 mmHg respectively 
in hypertensive patients who were on propranolol treatment 
during intravenous infusion with 0.016-0.032 mg epinephrine, 
equivalent to one or two phials of odontological local anaes-
thetic with 1:100,000 epinephrine. When these same patients 
are treated with metoprolol (cardio selective beta blocker) 
infusions of epinephrine only provoke an increase of systolic 
arterial pressure of 5-11 mmHg and does not produce any 
change in diastolic arterial pressure (2). Similarly in healthy 
38-46 year old subjects previously treated with propranolol 
when carrying out intravenous infusion with 0.015 mg of epi-
nephrine a pronounced hypertension is produced with reflex 
bradicardia. The peripheral resistance which normally falls 
after administering a moderate dose of epinephrine increases 
and this produces an increase in a dose dependent arterial 
pressure and a slowing down of cardiac reflex. Metaprolol 
does not have this effect. However, both selective and non-
selective beta blockers reduce the elimination of epinephrine 
and norepinephrine in the blood stream which could lightly 
increase arterial pressure. The pharmacological interaction 
between non- selective beta blockers and epinephrine used 
in local anaesthetic has been shown (2,13). Although local 
anaesthetics with epinephrine injected intradermally produce 
slight pharmacological interactions, intravenous injection of 
a small quantity of epinephrine, such as 15 micrograms, equi-
valent to 5/6 phial of 1:100,000 epinephrine, can produce a 
bradicardia reflex. Adverse reactions including cardiac arrest 
following injection the equivalent of 2 phials of 2% lidocaine 
with 1:50,000 epinephrine have been reported as being a con-
sequence of an interaction between non selective beta bloc-
kers and epinephrine. Epinephrine and levonordephrine can 
be used in patients taking beta blockers. However, the doses 
used are minimal: ½ phial of local anaesthetic with 1:100,000 
epinephrine and carefully injected to avoid administering it 
intravascularly (13). It is recommended to continue monito-
ring the patient as follows: inject the patient, wait five minutes 
and if there is no change in cardiovascular parameters the 
anaesthetic can be repeated at 5 minute intervals with conti-
nuous monitoring. More than 0.04 mg of epinephrine or 0.2 
mg of levonordephrine should not be administered (2 phials 
of 1:100,000 epinephrine or 1:20,000 levonordephrine) (1). 
Cleaning gum filaments impregnated with epinephrine should 
also be avoided in these patients. Given the potential danger 
of this pharmacological interaction and the large number of 
existing publications one should always take this into account 
before beginning dental treatment with local anaesthetics with 
vasoconstrictors (3,18,19).
Interaction of vasoconstrictors with general anaes-
thetics
Halothane, thiopental and barbiturates with very short activity 
are general anaesthetics that are able to increase the disrhyth-
mic effects of dental vasoconstrictors. Halothane is the most 
problematic. The mechanism by which these general anaes-
thetics increase disrhythmic activity of the vasoconstrictors 
appears to be due to the simultaneous stimulation of both 
medicaments with alpha and beta receptors (1). Epinephrine 
and levonordephrine are able to activate both receptors and 
unchain disrhythmic episodes during general anaesthesia. 
Generally, when carrying out odontological treatment un-
der general anaesthesia the odontologist should inform the 
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anaesthetist  that on administering a local anaesthetic with 
vasoconstrictor he should take into consideration the dose 
limit recommended for the vasoconstrictor according to 
general anaesthetic procedures: halothane (2 micrograms 
epinephrine/kg), enfluorane (3.5 micrograms epinephrine/
kg, isofluorine (5.5 micrograms epinephrine/kg) (1,3). 
Regarding this interaction a death resulted using a gum 
cleaning filament impregnated with epinephrine during an 
odontological treatment under general anaesthetic. This re-
inforces the general prohibition of the use of epinephrine in 
a concentrated form where there is a possibility of a potential 
pharmacological interaction (20).
Interaction of vasoconstrictors with cocaine
Cocaine was introduced in medicine in1884 as the first local 
anaesthetic. It was mixed with epinephrine in 1903 to increase 
the clinical efficacy of cocaine. In 1924 use of these medica-
ments was stopped as the result of various deaths produced. 
Actually cocaine is used as topical anaesthetic in mucous 
membranes and more so mixed with epinephrine for nasal 
surgery. Certainly illegal use is much more extended. Cocaine 
presents a pharmacological complex as an anaesthetic as it 
blocks the nervous conduction a similar way to lidocaine. As 
a stimulant, it inhibits the recaptation (via presynaptic nervous 
terminals) of norepinephrine, dopamine and serotonin (Figure 
3). This activity, similar to tricyclic antidepressors potentiates 
the adrenergic effects of vasoconstrictors (Figure 2). There is 
evidence that cocaine can increase the liberation of adrenergic 
neurotransmittors and intensify the postsynaptic response. 
It also blocks the cardiac muscarine receptors and produces 
a central alteration in the activity of the autonomic central 
nervous system.  All of which can additionally contribute to 
exaggerated responses on injecting vasoconstrictors in local 
anaesthetics used in odontology (21). The potential pharmaco-
logical interaction between vasoconstrictors and cocaine was 
clearly shown in both human and animal experiments (13). 
There is a well documented case of a myocardial infarction in 
a young healthy adult administered an injection of lidocaine 
with epinephrine after a topical application of cocaine for 
nasal surgery (8,22). Deaths have also been reported both 
in medicine and odontology as a result of the combination 
of vasoconstrictors and cocaine (23). The most important 
problem for odontologists is the fact that he is unaware that 
the patient requesting surgical treatment in out-patients is 
taking drugs. Therefore it is essential to be aware of possible 
signs of cocaine abuse, lesions in nasal walls and skin lesions. 
Dental treatment including the use of vasoconstrictors should 
be avoided for at least 48 hours after the last intake of cocaine 
because of agitation, hypertension and cardiac arrhythmia. 
Patients with cardiopàthy associated with cocaine or suspec-
ted of being under the influence of cocaine should be treated 
in hospitals as in-patients.
Interaction of vasoconstrictors with blocking adre-
nergic neuron
Guanethidine and guanadrel are medicaments that block 
adrenergic neurons. It inhibits the liberation of norepinephrine 
via the sympathetic nervous terminals (13). Prolonged use of 
these medicaments in treating arterial hypertension can result 
in adrenergic receptors to be hyper-regulated by the body in 
order to restore normal neurotransmission. An increase in the 
number of receptors and/or sensitivity could produce a hyper-
response to adrenergic vasoconstrictor. Blocked neurons can 
also increase the effect of epinephrine via a mechanism of 
competitive inhibition of the recaptation neuronal system. 
Blocking adrenergic neurons are used infrequently. However, 
in patients under treatment with these blockers the dose of 
epinephrine should not exceed 0.054 mg followed by careful 
aspiration. Levonordephrine and norepinephrine should be 
avoided (2,8).
Interaction of vasoconstrictors with thyroid hor-
mones
Thyroid hormones are produced by the thyroid glands. They 
are responsible for the increase of basal metabolism, which 
is essential for fetal development and proper functioning 
of cardiovascular, skeleto-muscle and hematopoietic sys-
tems as well as for corporal response regarding production 
of heat, oxygen consumption and the regulation of other 
hormonal systems. There are three circulating hormones: 
T4 (tetraiodotironine or tyroxine), T3 or triodotironine and 
Fig. 3. Mechanism of the action of cocaine 
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reverse T3 (biologically inactive). The plasma levels of the-
se hormones are maintained stable throughout life, except 
during the neonatal period and sometimes during the use of 
some medicaments in some illnesses. Hypothyroidism is the 
reduction of thyroid hormone levels which can be asympto-
matic giving rise to multiple symptoms and signs of diverse 
intensity in the whole organism. Untreated hypothyroidism 
carries a high mortality risk. The substitution of thyroid 
hormones is normally carried out with oral levothyroxine. 
Hyperthyroidism is a pathology caused by oversecretion of 
thyroid hormones (free T4, or free T3 or both) resulting in 
abnormally raised levels of plasma. The main cause is Grave´s 
disease or diffuse toxic goitre, toxic thyroid adenoma, toxic 
multinodular goitre and sub-acute thyroiditis. Inappropriate 
use of tyroxine and other preparations of thyroid hormones 
can cause cardiovascular changes as a result of increased 
concentrations of epinephrine (tachycardia, disrhythmia, 
pulse alterations or myocardial ischemia). For many years 
it was thought that the thyroid hormone and epinephrine 
interacted synergically to create these effects. However, 
evidence accumulated over the last decades show that the 
hemodynamic response to epinephrine and norepinephrine 
are nor significantly altered in patients with hyperthyroidism. 
Patients with large quantities of thyroid hormones in the blood 
stream develop cardiovascular pathologies as a result of the 
overstimilation of myocardial metabolism (24). Therefore it 
is recommended that adrenergic vasoconstrictors are used 
with caution in patients with evidence of excessive thyroid 
stimulation when being treated (13).
Interaction of vasoconstrictors with monoaminooxi-
dase inhibitors (MAOI)
The efficacy of MAOI antidepressors (isocarboxazides, phen-
ylzine, tranylcypromine, furazolidine, antimicrobial agents 
and seligilinine, -antiparkinson) is comparable to tricyclic an-
tidepressors, but there are patients who respond better to the-
se, similar to those patients who suffer the so-called ¨ ”atypical 
depression” or accompanied by intense anxiety or phobias. 
It is also used in depression resistant to other antidepressors 
(1). Traditional MAOI are non-specific irreversible inhibitors. 
Actually non-selective reversible inhibitors have been deve-
loped with less cardiovascular risks (although not as effective 
as the irreversibles) (Table 2). MAOI blocks the intraneuronal 
degradation of the norepinephrine in sympathetic nerves by 
MAO thus increasing the quantity of neurotransmittors capa-
ble of being liberated by adrenergic medicaments by indirect 
activity such as amphetamine, pseudofedrine (commonly 
found in nasal decongestions) and tyramine (amino acid pre-
sent in various foods like cheese). Accordingly the capacity 
of MAOI to totally and non-selectively inhibit MAO favors 
the accumulation of exogenic vasopressor amines, which 
appears as a hypertensive crisis on consumption of these me-
dicaments or food rich in tyramine. However, the frequency 
and seriousness of this phenomenon is less than previously 
thought. MAOI has already been implicated in interactions 
with various adrenergic amines resulting from its activity 
(avoiding the metabolism of metabolised medicaments by 
MAO) suggesting the existence of a potentially dangerous 
interaction between these antidepressors and vasoconstrictors 
in odontological use. However, clinical studies in human and 
animals have shown that cardiovascular interactions between 
MAOI and dental vasoconstrictors are not produced (8,13,25). 
Neither have pharmacological interactions between the se-
lective inhibitors of the recaptation serotonin (Table 2) and 
odontological vasoconstrictors been shown (26).
Interaction of vasoconstrictors with cathecol-o-
methyltransferase inhibitors
Treatment of Parkinson´s disease has incorporated new 
medicaments such as tolcapone (Tasmar®) and entacapone 
(Comtan®) used together with levadope/carbidope. On rever-
sibly blocking the cathecol-o-methyltransferase enzyme the 
inactivity of peripheral levodope is inhibited. The inactivity 
of epinephrine and levonordephrine administered exogeni-
cally, as they are substrates for cathecol-o-methyltransferase, 
can also be inhibited. These medicaments are relatively new 
and should be used cautiously in local anaesthesia (27). The 
European Agency for Medicaments (EAM) withdrew tolca-
pone for producing fulminating hepatitis, rabdomyolisis and 
malignant neuroleptic syndrome. Previously, in a switch study 
against entacapone, a non-significant tendency was observed 
but beneficial for tolcapone. Data available are insufficient 
to know the risk-benefit relationship (28). In odontologically 
managing these patients it is recommended to initially ad-
minister a phial of lidocaine with epinephrine 1:100,000 and 
to monitor the arterial pressure and cardiac frequency of the 
patient before administering an additional injection of local 
anaesthetic with vasoconstrictor (2).
Interaction of vasoconstrictors with digital glucosides
Digoxin is the most frequently used cardiotonic glucoside in 
the treatment of insufficient cardiac congestion. Digoxin is a 
classical vegetal cardiotonic therapeutically used since Gallic 
times (29). In insufficient cardiac congestion therapy it is a 
medicament in the second line after diuretics and inhibitors 
of enzyme converters of angiostensine-aldosterone. Although 
this improves tolerance of diuretic requirements and reduces 
exacerbations of insufficient cardiac congestion, it has a 
narrow therapeutic margin (with the consequent danger of 
digital intoxication) (3) and an adverse critical effect like 
ventricular arrhythmias, which raises the risk of acute myo-
cardial infarction (1,30). Patients undergoing treatment with 
digoxin are more fragile as a result of their basic pathology 
when undergoing dental treatment. Therefore the use of 
vasoconstrictors in these patients should be carried out cau-
tiously as excessive doses of epinephrine or levonordephrine 
can induce a disrhythmic activity. Careful aspiration prior to 
administering local anaesthetic should be carried out as well 
as limiting the dose of epinephrine or levonordephrine from 
0.04 to 0.20 mg respectively (1,3).
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Conclusions
The odontologist should be aware of the importance of iden-
tifying and preferably preventing the appearance of pharma-
cological interactions and the possible consequent adverse 
reactions during bucal cavity treatment. Correct medical 
history with special note of medicament taken by the patient 
is essential in preventing pharmacological interactions. Ad-
ministration of local anaesthetics with vasoconstrictors can 
produce severe repercussions. It is also important to know 
the mechanisms by which these interactions can be produced 
in order to avoiding them. The sympatheticomimetical effect 
of epinephrine in local anaesthetics can be intensified by the 
simultaneous administration of tricyclic antidepressors and 
non-selective cardio beta blockers, which could lead to in-
creased arterial blood pressure. Certain general anaesthetics, 
like halothane, can sensitize the heart to catecholamines thus 
induce arrhythmias after administration of anaesthetic with 
epinephrine. Treatment of patients with cocaine addiction 
(including use of vasoconstrictor) should be avoided for at 
least 48 hours after the last cocaine intake.
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